The complete set of logistic regression analysis data for all SNPs are provided in the Excel files for Supplementary Tables [1](#pone.0150467.t001){ref-type="table"} and [2](#pone.0150467.t002){ref-type="table"}.

Introduction {#sec001}
============

Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases \[[@pone.0150467.ref001]\]; approximately one fifth (20%) of NSCLC patients have locally advanced (stage III) disease at the time of diagnosis \[[@pone.0150467.ref002]\] and have a poor 5-year survival rate (lower than 14%) \[[@pone.0150467.ref003]\]. Radiotherapy combined with chemotherapy is the mainstay for locally advanced NSCLC \[[@pone.0150467.ref004]\]. It can enhance control of local disease and to improve 5 year survival rate by 4.5% \[[@pone.0150467.ref005]--[@pone.0150467.ref006]\]. However, radiation-induced toxicity to normal tissue often limits the efficacy of definitive radiation therapy. Severe acute esophagitis and symptomatic pneumonitis occur in approximately 15--25% and 5--50% of NSCLC patients, respectively \[[@pone.0150467.ref007]--[@pone.0150467.ref008]\]. These toxic effects are dose-limiting and can compromise treatment outcomes.

Currently, clinical and dosimetric factors are used to predict the possibility of radiation-induced toxicities and to guide dose design \[[@pone.0150467.ref009]--[@pone.0150467.ref010]\]. However, these clinical factors lack sufficient accuracy in the prediction of these toxicities, with limited negative predictive values (60% -- 80%) and high false-negative rates (25% -- 50%) \[[@pone.0150467.ref011]\]. Therefore, there is a strong need to identify novel biomarkers to assist in the accurate prediction of these toxicities and to guide radiation dose design before treatment. Genetic variations appear to be promising biomarkers, as they have been associated with radiotherapy toxicities in many studies \[[@pone.0150467.ref012]--[@pone.0150467.ref014]\]; however most of these studies focused on only a limited number of genes.

MicroRNA (miRNA) is a class of small non-coding RNAs that regulates gene expression by binding to the target mRNA. MiRNAs play an important role in cancer development and therapeutic responses \[[@pone.0150467.ref015]--[@pone.0150467.ref016]\]. Evidence has linked miRNAs with radiation-induced side effects such as hematopoietic injury \[[@pone.0150467.ref017]\]. Previous study has also reported that genetic variation within miRNA processing genes or miRNA-mRNA binding sites could influence miRNA maturation or regulation \[[@pone.0150467.ref018]\] and were associated with clinical outcomes in NSCLC patients \[[@pone.0150467.ref019]\].

In this study, we analyzed 161 SNPs within predicted microRNA binding sites genes in major cancer-related genes and 72 SNPs in microRNA processing genes. We evaluated the relationship between these variants and radiation-induced pneumonitis and esophagitis in patients with locally advanced NSCLC treated with definitive radiation therapy. Using Silicon bioinformation queries (Silicon Genetics), we functionally characterized the potential mechanism of identified loci. To our knowledge, ours is the first effort to comprehensively evaluate the effect of miRNA-related genetic variations on the risk of developing radiation-induced toxicities.

Material and Methods {#sec002}
====================

Ethics statement {#sec003}
----------------

This study was approved by the institutional review board (IRB) of MD Anderson Cancer Center (Houston, TX), and written informed consent was obtained from all participants according to procedures approved by IRB.

Study population and data collection {#sec004}
------------------------------------

All patients had histologically confirmed, newly diagnosed NSCLC and were recruited from MD Anderson Cancer Center between September 1995 and February 2008. Patient eligibility criteria for the study were locally advanced stage III NSCLC, Caucasian race, treated with primary radiation therapy (with or without chemotherapy). In addition, for cases treated with concurrent chemoradiotherapy, all were subjected to platinum-based chemotherapy. Clinical stage was defined according to American Joint Committee on Cancer (AJCC) staging system (version 6).

A questionnaire was used to collect epidemiologic data during an in-person interview. Blood sample of patients were drawn from each patient. Clinical variables and follow-up information were abstracted from medical records. Radiation-induced toxicities were defined following the criteria defined previously (19). Briefly, we used documentation of new-onset pain upon swallowing that occurred during treatment to define esophagitis and we used roentgenographic or CT scan abnormalities that were often associated with nonproductive cough and/or fever to detect pneumonitis. Radiation-induced toxicities graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) guidelines \[[@pone.0150467.ref019]\]. We defined an event as the occurrence of a severe (grade ≥2) pneumonitis or esophagitis.

SNP selection and genotyping {#sec005}
----------------------------

The details of the SNP selection were described previously \[[@pone.0150467.ref020],[@pone.0150467.ref021]\]. Briefly, we previously developed a panel that included major genes in cancer-related pathways \[[@pone.0150467.ref021]\], among which there were seven microRNA processing genes. Tagging SNPs (±10 kb flanking each gene) and potential functional SNPs for each gene were included. MiRNA binding site SNPs were identified using the PolymiRTS v3.0 \[[@pone.0150467.ref022]\] for the genes included on the chip. Genomic DNA was extracted from the study patients' peripheral blood using the Human Whole Blood Genomic DNA Extraction Kit (Qiagen, Valencia, CA). Genotyping was performed using Custom Illumina iSelect Infinium II Beadchips following the standard protocol (Illumina, San Diego, CA). Only SNPs with a sample call rate greater than 95% and samples with an SNP call rate greater than 95% were included in the final analysis.

Statistical analysis {#sec006}
--------------------

Chi-square test, Fisher's exact test and student's t-test were used to analyze the distribution of demographic and clinical variables between patients with or without toxic reactions. Multivariate logistic regression was used to assess the main effect of single SNP on the risk of developing pneumonitis or esophagitis, adjusted for patient age, sex, performance status, smoking status, clinical stage of disease, radiation therapy type, chemotherapy, radiation dosimtric variables, and lung function. A complete analysis of the effect of all 233 individual SNPs on risk of esophagitis and pneumonitis are shown in [S1 Table](#pone.0150467.s002){ref-type="supplementary-material"} and [S2 Table](#pone.0150467.s003){ref-type="supplementary-material"}, respectively. Multiple hypothesis testing adjustment was performed using the \"q-value\" package in R software \[[@pone.0150467.ref023]\] based on a false discovery rate of 10% that has been used in prior studies of clinical outcomes \[[@pone.0150467.ref024]--[@pone.0150467.ref026]\]. Cumulative effects were analyzed by calculating unfavorable genotypes (UFGs), which were defined as counting the number genotypes from the identified SNPs (p\<0.01) associated with an increased risk of developing radiation-induced toxicity. All the analyses above were performed using STATA software (version 10, STATA Corp., College Station, TX). Gene-based analysis was performed using Versatile Gene-Based Association Study software (VEGAS) \[[@pone.0150467.ref027]\]. Expression Quantitative Trait Loci (eQTL) analysis was conducted using the Genevar \[[@pone.0150467.ref028]\] (GENe Expression VARiation) database(<http://www.sanger.ac.uk/resources/software/genevar/>). The results were based on data for the Multiple Tissue Human Expression Resource (MuTHER) Study \[[@pone.0150467.ref029]\]. The potential miRNA binding site SNPs were identified using PolymirTS v1.0 (Table A and Table B in [S1 File](#pone.0150467.s001){ref-type="supplementary-material"}). Spearman's correlations were obtained for SNPs and the corresponding mapped genes to perform cis-eQTL. A two-side value of p\<0.05 was considered statistically significant.

Results {#sec007}
=======

Host characteristics {#sec008}
--------------------

A total of 167 patients were included in this study; 71% of patients had grade 2 or higher esophagitis, 38% of patients had grade 2 or higher pneumonitis, and 28% of patients had both esophagitis and pneumonitis ([Table 1](#pone.0150467.t001){ref-type="table"}). There was no significant difference between patients with or without severe toxicities for both esophagitis and pneumonitis in terms of age, sex, smoking pack years, Carbon Monoxide Diffusing Capacity (DLCO), expiratory volume in 1 second (FEV1), planning target volume (PTV), clinical stage of disease, performance status or chemotherapy. The majority of the patients (\>95%) were treated with concurrent, platinum-based chemoradiotherapy. Both radiation dosimetrics and radiotherapy type exhibited significant difference between patients with or without esophagitis. Mean esophageal dose was significantly higher for patients with esophagitis (36.79±10.69Gy) than those without esophagitis (30.62±9.32Gy) (p = 0.04). Mean lung radiation dose for patients with pneumonitis was significantly higher (23.03±11.98Gy) than those without pneumonitis (18.86±5.22Gy) (p = 0.01).

10.1371/journal.pone.0150467.t001

###### Characteristics of Patients with Stage III NSCLC by Esophagitis and pneumonitis Status.

![](pone.0150467.t001){#pone.0150467.t001g}

  Characteristics                               Esophagitis Status   Pneumonitis Status                                                                                                                         
  --------------------------------------------- -------------------- -------------------- --------------------------------------------------------------------------------- ----------------- ----------------- --------------------------------------------
  **Age, mean(SD)**                             60.65 (10.04)        62.83 (9.94)         0.203                                                                             62.55 (9.46)      60.63 (9.97)      0.234
  **Smoking Pack year, mean(SD)**               47.87 (29.63)        42.41 (24.44)        0.259                                                                             47.32 (32.04)     45.05 (24.37)     0.616
  **DLCO(mL), mean(SD)**                        70.32 (16.90)        70.29 (22.70)        0.997                                                                             67.67 (15.25)     72.54 (21.24)     0.441
  **FEV1(mL), mean(SD)**                        73.96 (17.52)        71.59 (19.74)        0.682                                                                             72.13 (15.34)     73.62 (20.41)     0.803
  **PTV(mL), mean(SD)**                         908.50 (504.64)      728.21 (452.80)      0.106                                                                             844.00 (561.11)   846.57 (473.85)   0.982
  **Mean Esophageal Dose (Gy) mean(SD)**        36.79 (10.69)        30.62 (9.32)         0.004[\*](#t001fn005){ref-type="table-fn"}                                        35.52 (11.76)     34.25 (10.38)     0.569
  **Mean Lung Dose (Gy) mean(SD)**              21.31 (9.3)          18.05 (4.4)          0.048                                                                             23.03 (11.98)     18.86 (5.22)      0.015[\*](#t001fn005){ref-type="table-fn"}
  **Sex**                                                                                                                                                                                                       
  **    Male, n (%)**                           64 (54)              27 (56)              0.772                                                                             31 (52)           53 (55)           0.717
  **    Female, n (%)**                         55 (46)              21 (44)                                                                                                29 (48)           44 (45)           
  **Clinical Stage of Disease**                                                                                                                                                                                 
  **    IIIA, n (%)**                           64 (54)              28 (58)              0.593                                                                             36 (60)           52 (54)           0.432
  **    IIIB, n (%)**                           55 (46)              20 (42)                                                                                                24 (40)           45 (46)           
  **Performance status**                                                                                                                                                                                        
  **    0, n (%)**                              41 (34)              10 (21)              0.161[\^](#t001fn006){ref-type="table-fn"}                                        18 (30)           31 (32)           0.417[\^](#t001fn006){ref-type="table-fn"}
  **    1, n (%)**                              52 (44)              27 (56)                                                                                                29 (48)           43 (44)           
  **    2\~4, n (%)**                           8 (7)                6 (13)                                                                                                 3 (5)             11 (11)           
  **    Missing, n (%)**                        18 (15)              5 (10)                                                                                                 10 (17)           12 (12)           
  **Chemotherapy**                                                                                                                                                                                              
  **    concurrent chemoradiotherapy, n (%)**   117 (98)             44 (92)              0.057[\^](#t001fn006){ref-type="table-fn"}                                        58 (97)           93 (96)           1\^
  **    Others, n (%)**                         2 (2)                4 (8)                                                                                                  2 (3)             4 (4)             
  **Radiotherapy type**                                                                                                                                                                                         
  **    2D, n (%)**                             31 (26)              12 (25)              0.021[\^](#t001fn006){ref-type="table-fn"}[\*](#t001fn005){ref-type="table-fn"}   14 (23)           28 (29)           0.578[\^](#t001fn006){ref-type="table-fn"}
  **    3D, n (%)**                             56 (47)              14 (29)                                                                                                29 (48)           36 (37)           
  **    IMRT, n (%)**                           29 (24)              16 (33)                                                                                                15 (25)           27 (28)           
  **    Proton, n (%)**                         3 (3)                6 (13)                                                                                                 2 (3)             6 (6)              

DLCO: Carbon Monoxide Diffusing Capacity

FEV1: expiratory volume in 1 second

PTV: planning target volume

IMRT: Intensity-modulated radiation therapy

\^ Fisher\'s exact test

\*p\<0.05.

Associations between individual SNPs and radiation-induced acute esophagitis {#sec009}
----------------------------------------------------------------------------

In all, 233 SNPs (161 SNPs from predicted microRNA binding sites and 72 SNPs from microRNA processing sites) were included in the analysis. We found 16 SNPs significantly associated with a risk of developing esophagitis at p\<0.05 ([Table 2](#pone.0150467.t002){ref-type="table"}), including 13 SNPs located in microRNA binding sites and 3 SNPs in microRNA processing genes. The predictive miRNAs that may potentially target these binding sites are listed in Table A in S1 file. After multiple comparison corrections, three SNPs (*RPS6KB2*:rs10274, *SMO*:rs1061280, *SMO*:rs1061285) remained significantly associated with esophagitis (q\<0.1) ([Table 2](#pone.0150467.t002){ref-type="table"}). Patients with the AA genotype of *RPS6KB2*:rs10274 has an 81% reduced risk of developing esophagitis (OR: 0.19, 95% CI: 0.07--0.51, p = 0.001, q = 0.06). Patients with AG+GG genotype of *SMO*:rs1061280 (in high LD with *SMO*:rs1061285, *r*^2^\>0.8) had an 81% reduced risk of developing esophagitis (OR: 0.19, 95% CI: 0.07--0.53, p = 0.001, q = 0.06).

10.1371/journal.pone.0150467.t002

###### Association of Esophagitis with the top 16 MicroRNA SNPs.

![](pone.0150467.t002){#pone.0150467.t002g}

  SNP          Gene       Site         Chr   Allelic change   Model[\*](#t002fn001){ref-type="table-fn"}   OR (95% CI)[^\#^](#t002fn004){ref-type="table-fn"}   *p*
  ------------ ---------- ------------ ----- ---------------- -------------------------------------------- ---------------------------------------------------- --------------------------------------------
  rs10274      RPS6KB2    binding      11    G\>A             rec                                          0.19 (0.07--0.51)                                    0.001[\^](#t002fn005){ref-type="table-fn"}
  rs1061280    SMO        binding      7     A\>G             dom                                          0.19 (0.07--0.53)                                    0.001[\^](#t002fn005){ref-type="table-fn"}
  rs1061285    SMO        binding      7     C\>A             dom                                          0.19 (0.07--0.53)                                    0.001[\^](#t002fn005){ref-type="table-fn"}
  rs3124591    NOTCH1     binding      9     A\>G             add                                          0.39(0.20--0.75)                                     0.005
  rs1133043    GPR30      binding      7     C\>G             rec                                          0.16(0.04--0.64)                                     0.01
  rs16950113   SMAD7      binding      18    A\>G             dom                                          0.23(0.07--0.75)                                     0.015
  rs713065     FZD4       binding      11    G\>A             add                                          2.36(1.14--4.89)                                     0.02
  rs2740351    GEMIN4     processing   17    A\>G             add                                          2.15(1.12--4.12)                                     0.022
  rs7813       GEMIN4     processing   17    A\>G             add                                          2.15(1.12--4.12)                                     0.022
  rs2075993    E2F2       binding      1     A\>G             rec                                          0.32(0.11--0.90)                                     0.03
  rs7588       PLK1       binding      16    G\>A             dom                                          0.40(0.17--0.92)                                     0.031
  rs573010     RNASEN     processing   5     C\>A             rec                                          0.14(0.02--0.84)                                     0.031
  rs1052133    OGG1       binding      3     C\>G             add                                          2.34(1.07--5.10)                                     0.033
  rs4690150    FGF5       binding      4     C\>G             dom                                          2.53(1.06--6.01)                                     0.036
  rs2248718    ATP6V1C1   binding      8     G\>A             add                                          0.49(0.25--0.98)                                     0.043
  rs4246215    FEN1       binding      11    C\>A             dom                                          2.51(1.03--6.10)                                     0.043

\* add, additive

dom, dominant

rec, recessive

^\#^ Adjusted for age, sex, clinical stage, performance status, smoking status, radiation therapy type, radiation treatment type and dose and lung function

\^ p value \<0.05 and q value\< 0.1.

To evaluate the potential cumulative effects of these SNPs, we selected top SNPs (p\<0.01) and performed unfavorable genotype (UFG) analysis. *RPS6KB2*:rs10274 (GA+GG), *SMO*:rs1061280 (AA), *NOTCH1*:rs3124591 (AG+GG), and *GPR30*: rs1133043 (CG+GG) were defined as UFGs, and were included in the analysis ([Table 3](#pone.0150467.t003){ref-type="table"}). Significant dose-response effects were identified: with the increase in the number of UFGs, the risk of developing esophagitis (P-trend = p: 1.03×10^−6^) significantly increased accordingly. Compared with patients with 0--1 UFG, those patients with 2 UFGs had 3.33-fold increased risk of esophagitis (OR: 3.33, 95%CI: 1.19--9.33, p: 0.02). Patients with 3 or 4 UFGs had more than a 13-fold increased risk of developing esophagitis (OR: 13.44, 95% CI: 4.40--41.07, *p*: 5.11×10^−6^).

10.1371/journal.pone.0150467.t003

###### Cumulative effect of unfavorable SNPs on esophagitis or pneumonitis.

![](pone.0150467.t003){#pone.0150467.t003g}

  No. unfavorable SNPs                                 Events       No event     OR(95%CI)              *p*
  ---------------------------------------------------- ------------ ------------ ---------------------- -------------
  *Esophagitis*[\*](#t003fn001){ref-type="table-fn"}                                                    
  0--1                                                 14(36.84%)   24(63.16%)   1(reference)           
  2                                                    49(52.13%)   45(47.87%)   3.33 (1.19--9.33)      0.02
  3--4                                                 79(69.30%)   35(30.70%)   13.44 (4.40--41.07)    5.11×10^−6^
  *P* trend                                                                      3.00 (1.93--4.67)      1.03×10^−6^
  *Pneumonitis*[\^](#t003fn002){ref-type="table-fn"}                                                    
  0                                                    37(29.37%)   89(70.63%)   1(reference)           
  1                                                    44(43.56%)   57(56.44%)   1.88 (1.02--3.46)      0.044
  2                                                    6(85.71%)    1(14.29%)    55.89 (3.69--845.54)   0.004
  *P* trend                                                                      2.48 (1.43--4.29)      0.001

\*rs10274, rs1061280, rs3124591 and rs1133043 were included in the analysis; rs1061285 was dropped for the linkage with rs1061280

\^rs720014 and rs7957 were included in the analysis; rs3757 and rs1633445 were dropped for the linkage with rs720014.

Associations between individual SNPs and radiation-induced acute pneumonitis {#sec010}
----------------------------------------------------------------------------

In all, 11 SNPs (6 SNPs in microRNA binding sites and 5 SNPs in microRNA processing genes) were significantly associated with pneumonitis ([Table 4](#pone.0150467.t004){ref-type="table"}). The predictive miRNAs that may potentially target the binding site variants are listed in Table B in [S1 File](#pone.0150467.s001){ref-type="supplementary-material"}. The most significant SNP, rs720014 (in high LD with rs3757 and rs1633445, *r*^2^\>0.8), was located in 3' UTR of *DGCR8* gene. Patients with GG+GA genotype of *DGCR8*:rs720014 had 3.54- fold increased risk of pneumonitis (OR: 3.54, 95% CI: 1.65--7.61, p \<0.05). This SNP remained significant associated with pneumonitis after multiple comparison corrections (q\<0.1).

10.1371/journal.pone.0150467.t004

###### Association of Pneumonitis with the top 11 MicroRNA SNPs.

![](pone.0150467.t004){#pone.0150467.t004g}

  SNP          Gene        Site         Chr   Allelic change   Model[\*](#t004fn001){ref-type="table-fn"}   OR (95% CI)[^\#^](#t004fn004){ref-type="table-fn"}   *p*
  ------------ ----------- ------------ ----- ---------------- -------------------------------------------- ---------------------------------------------------- --------------------------------------------
  rs720014     DGCR8       processing   22    A\>G             dom                                          3.54(1.65--7.61)                                     0.001[\^](#t004fn005){ref-type="table-fn"}
  rs3757       DGCR8       processing   22    G\>A             dom                                          3.54(1.65--7.61)                                     0.001[\^](#t004fn005){ref-type="table-fn"}
  rs1633445    DGCR8       processing   22    A\>G             dom                                          3.54(1.65--7.61)                                     0.001[\^](#t004fn005){ref-type="table-fn"}
  rs7957       TNFRSF10D   binding      8     A\>G             add                                          2.44(1.25--4.75)                                     0.009
  rs3087833    GEMIN4      processing   17    G\>A             add                                          2.22(1.21--4.07)                                     0.01
  rs724710     BCL2L11     binding      2     G\>A             dom                                          2.6(1.21--5.57)                                      0.014
  rs573010     RNASEN      processing   5     C\>A             dom                                          2.43(1.14--5.20)                                     0.022
  rs2248718    ATP6V1C1    binding      8     G\>A             dom                                          2.42(1.09--5.35)                                     0.03
  rs4037       ALDH18A1    binding      10    G\>A             rec                                          0.25(0.07--0.91)                                     0.036
  rs7669660    ADH5        binding      4     A\>G             dom                                          0.37(0.14--0.96)                                     0.041
  rs16950113   SMAD7       binding      18    A\>G             dom                                          2.96(1.01--8.65)                                     0.047

\* add, additive

dom, dominant

rec, recessive

^\#^ Adjusted for age, sex, clinical stage, performance status, smoking status, radiation therapy type, radiation treatment type and dose and lung function

\^ q value\< 0.1.

Using the same approach as in the esophagitis analysis, we also performed UFG analysis for the top SNPs (p\<0.01) identified for pneumonitis. *DGCR8*:rs720014 (GG) and *TNFRSF10D*:rs7957 (GG) were defined as UFGs and were included in the UFG analysis of pneumonitis ([Table 3](#pone.0150467.t003){ref-type="table"}). A significant dose-response effect was also observed for pneumonitis (P trend = 0.001) with increasing number of UFGs. Compared with patients with no UFG, patients with one UFG had a 1.88-fold increased risk of pneumonitis (OR: 1.88, 95% CI: 1.02--3.64, p: 0.044) and patients with two UFGs had more than a 50-fold increased risk of pneumonitis (OR: 55.89, 95% CI: 3.69--845.54, p = 0.004).

eQTL analysis {#sec011}
-------------

To explore the potential function and underlying mechanism for identified loci, we performed expression quantitative trait loci (eQTL) analysis using an online bioinformatics tool. All 27 SNPs significant for esophagitis (16 SNPs) and pneumonitis (11 SNPs) were entered into the analysis. Genevar showed that the genotype of rs10274 was associated with altered expression of the *RPS6KB2* gene based on data from the Multiple Tissue Human Expression Resource (MuTHER) Study, which analyzed gene expression in adipose and skin tissues as well as lymphoblastoid cell lines (LCLs) derived from 196 Caucasian female twins split into two groups. Compared with the GG genotype, the AA genotype of rs10274 was associated with lower expression of the *RPS6KB2* gene in all tissue types (adipose, skin, and LCLs); the correlation coefficient (rho) ranged from 0.215 to 0.37, and the P value ranged from 0.049 to 8.0×10^−4^ ([Fig 1A--1F](#pone.0150467.g001){ref-type="fig"}).

![The eQTL analysis of rs10274 based on Genevar Twin study samples.\
(A) RPS6KB2 expression in subcutaneous fat in Twin1 group; (B) RPS6KB2 expression in subcutaneous fat in Twin2 group; (C) RPS6KB2 expression in lymphoblastoid cell lines in Twin1 group; (D) RPS6KB2 expression in lymphoblastoid cell lines in Twin2 group; (E) RPS6KB2 expression in skin tissues in Twin1 group; (F) RPS6KB2 expression in skin tissues in Twin2 group.](pone.0150467.g001){#pone.0150467.g001}

Gene-based analysis {#sec012}
-------------------

Because multiple SNPs were analyzed for each gene within the miRNA processing pathway, to summarize the total effects contributed by SNPs within a single gene, we performed a gene-based analysis using VEGAS \[[@pone.0150467.ref023]\], which tests the association for multiple SNPs in a pre-defined set and takes into account the linkage disequilibrium structure. This software performed simulations using a less computationally intensive Monte Carlo approach. We observed that *DGCR8* (p value: 0.010) and *GEMIN4* (p value: 0.039) were significantly associated with pneumonitis, while *XPO5* reached borderline significance (P = 0.087). However, only *DGCR8* remained significant after adjustment for multiple testing at false discovery rate (FDR) of 10%). *GEMIN4* was the only gene that reached borderline significance for esophagitis (P = 0.065) ([Table 5](#pone.0150467.t005){ref-type="table"}).

10.1371/journal.pone.0150467.t005

###### Relationship between the microRNA processing gene and radiation toxicity.

![](pone.0150467.t005){#pone.0150467.t005g}

                     Esophagitis   Pneumonitis
  ---- -------- ---- ------------- -------------------------------------------
  22   DGCR8    13   0.629         0.01[\*](#t005fn002){ref-type="table-fn"}
  17   GEMIN4   7    0.065         0.039
  6    XPO5     4    0.364         0.087
  1    DDX20    5    0.348         0.151
  5    RNASEN   27   0.339         0.168
  12   RAN      5    0.387         0.503
  14   DICER1   11   0.284         0.56

Gene-based test by VEGAS

\*significant at FDR of 10%.

Discussion {#sec013}
==========

We identified genetic variations in miRNA-related genes that were significantly associated with the risk of developing radiation-induced pneumonitis and esophagitis. After multiple comparisons, *RPS6KB2* and *SMO* binding site SNPs remained significantly associated with radiotherapy-induced acute esophagitis, while *TNFRSF10D*:rs7957 was significantly associated with radiotherapy-induced acute pneumonitis. Gene based analysis supported a significant role of *DGCR8* and *GEMIN4* in the risk of pneumonitis. eQTL analysis showed that the top SNP (*RPS6KB2*:rs10274) for esophagitis analysis could potentially affect *RPS6KB2* expression. These results suggest that genetic variants in miRNA-related genes may serve as potential predictive markers of the risk of developing radiation-induced acute toxicities.

In our analysis, we found that *RPS6KB2*:rs10274 was the most significant SNP associated with the risk of esophagitis. The *RPS6KB2* gene encodes for protein S6 kinase 2 (S6K2), which affects many cellular processes such as cell proliferation, survival, and metastasis. *RPS6KB2* was also reported to have a role in acute radiation effects via the AKT/mTOR pathway \[[@pone.0150467.ref030]--[@pone.0150467.ref032]\]. *RPS6KB2* was found to be the direct target of mir*-193a-3p* \[[@pone.0150467.ref031]\]. We found that the AA genotype of *RPS6KB2*:rs10274 had a protective effect against the risk of esophagitis, and cis-eQTL analysis further supported that the AA genotype of rs10274 is associated with lower expression of the *RPS6KB2* gene, while the GG genotype of rs10274 was associated with higher expression of *RPS6KB2*. Although not yet reported in the literature, it is likely that the A genotype of *RPS6KB2*:rs10274 itself or SNP tagged by it could create a new miRNA binding site for miR-193a regulation, which would enable the down regulation of miR-193a-3p on the host gene. The decreased level of *RPS6KB2* expression in turn would protect the cell from radiation-induced toxicity through the AKT/mTOR pathway. Two SNPs (rs1061280 and rs1061285) in the *SMO* gene were also identified as significantly associated with the risk of esophagitis after multiple comparison corrections. Smoothened *(SMO)* encoded a protein that belongs to the G-protein--coupled receptor superfamily. As an important member of the hedgehog (Hh) pathway, this protein SMO was reported to have a driver role in the carcinogenesis of esophagus \[[@pone.0150467.ref033]\]. It is likely that the binding site SNPs (*SMO*: rs1061280, *SMO*: rs1061285) could affect *SMO* gene transcription or functions that contribute to the etiology of esophagitis after radiotherapy.

*TNFRSF10D*: rs7957 is the most significant binding site SNP identified for pneumonitis. *TNFRSF10D* belongs to the tumor necrosis factor receptor superfamily. *TNFRSF10D* can trigger activation of the AKT pathway \[[@pone.0150467.ref034]\], which contributes to acute radiation response and acute radiation toxicity \[[@pone.0150467.ref028]\]. We found that the GG genotype of rs7957 is associated with a higher risk of radiotherapy-induced pneumonitis and at the same time it confers a longer survival time (data not shown). This result may suggest that patients with a high risk of radiation toxicity are those who respond well to radiation. Biologically, the association between *TNFRSF10D* and radiation outcomes may be attributed to the activation of stem cell signaling via TNFRSF10D-activated AKT pathway. Activating stem cell signal pathways will start the repair of radiotherapy-induced cell necrosis or apoptosis \[[@pone.0150467.ref035],[@pone.0150467.ref036]\]; at the same time this activation will also promote the proliferation of cancer stem cells, which is the cause of cell resistance to therapy and of metastasis \[[@pone.0150467.ref037]\]. Consistent with this theory, the GG genotype of *TNFRSF10D*: rs7957 indicates higher risk of pneumonitis and longer survival duration, probably due to the activation of the stem cell pathway- AKT pathway. The role of stem cell signaling pathways in radiotherapy-induced side effects have not been reported. Our data suggest that the AKT/mTOR and SMO-Hh pathway probably contribute to radiotherapy-induced esophagitis, while the AKT pathway probably contributes to the pneumonitis.

By summarizing the effects from multiple SNPs in the same gene, the *DGCR8* and *GEMIN4* are the top genes identified for pneumonitis at the single gene level. *DGCR8* is an important gene that participates in microRNA processing \[[@pone.0150467.ref038]\] and helps in generating RNA hairpins known as pre-microRNA. Daniel Gomez-Cabello \[[@pone.0150467.ref039]\] found that *DGCR8* may participate in pneumonitis through affecting fibroblasts 'cell proliferation. Our results show that three SNPs in the *DGCR8* gene are among the top SNPs identified in pneumonitis, and gene-based analysis showed that the *DGCR8* gene is the most significant gene in the analysis of pneumonitis (P = 0.010). *GEMIN4* is another important microRNA processing gene that interacts with microRNA and forms a ribonucleoprotein to form the RNA-induced silencing complex \[[@pone.0150467.ref040]\]. *GEMIN4* contributes to carcinogenesis in many cancers, such as kidney \[[@pone.0150467.ref041]\] and ovarian cancer \[[@pone.0150467.ref042]\]. Here, we report that the AA genotype of *GEMIN4*: rs3087833 would confer a higher risk of radiation-induced pneumonitis.

This study is the first to comprehensively evaluate the effect of miRNA-related genetic variants on the risk of developing radiation-induced toxicities. However, our study also had a few limitations. First, because of the limited sample size and the paucity of comparable studies available, we did not include a validation step; instead, we performed multiple comparison corrections, which reduced the likelihood of false discovery. Nerveless, independent studies will be warranted to confirm our findings. Second, although eQTL analysis suggests that one of the SNPs may affect gene expression, the biological mechanisms underlying the association of these SNPs with radiation outcome are unclear. Mechanistic studies are needed to clarify the functional impact of the SNPs.

In conclusion, we have provided strong evidence that microRNA-related SNPs can contribute to the prediction of radiation-induced esophagitis and pneumonitis. eQTL analysis further suggests that microRNA binding site SNPs could affect miRNA regulation of host gene expression and thus influence the risk of developing radiotherapy-induced toxicities. Since radiotherapy is important for lung cancer patients, especially those with locally advanced NSCLC, our findings may assist in the customized planning of radiation dose based on the patients' risk of developing toxicities prior to treatment, thus maximizing treatment effects while minimizing toxicities that are sometimes life threatening.
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